NIH-funded research effort identifies most common symptoms, potential subgroups, and initial symptom-based scoring system – with aim of improving future diagnostics and treatment. Initial findings from a study of nearly 10,000 Americans, many of whom had COVID-19, have uncovered new details about long COVID, the post-infection set of conditions that can affect nearly every tissue
Since the start of the COVID-19 pandemic, a class of corticosteroids called glucocorticoids (GCs) have become established as one of the main treatment options, especially for severe cases, thanks to their anti-inflammatory and immunosuppressant action. Brazilian researchers recently discovered new ways in which these drugs influence the organism’s inflammatory response during an infection: they raise
Differences in Physiologic Variables in Patients With Postacute Sequelae of SARS-CoV-2 Infection (PASC, Red) Compared With Healthy Volunteers (HVs, Gray) Each dot represents 1 participant; bars represent standard errors of the mean (top edge of rectangle). p Values are for independent means t tests. (A) Heart rate (HR); (B) finger systolic blood pressure (BPs); (C) baroreflex-cardiovagal gain; (D) high-frequency
Secondary bacterial pneumonia that does not resolve was a key driver of death in patients with Covid, according to a study. The study was published in the Journal of Clinical Investigation. The scientists also found evidence that Covid does not cause a “cytokine storm”, so often believed to cause death. Secondary bacterial pneumonia that does
COVID-19 vaccination directly saved at least 1,004,927 lives across Europe between December 2020 and March 2023, according to new research being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark (15-18 April). The new estimates by WHO/Europe and presented at the conference by Dr Margaux Meslé, Epidemiologist at
A new antibody drug by pharmaceutical company inflaRx received FDA emergency use authorization to treat critically ill Covid-19 patients. One of the greatest hurdles for monoclonal antibody development during the Covid-19 pandemic is the ongoing mutation of the SARS-CoV-2 virus. Most antibodies introduced throughout the pandemic targeted the virus spike protein, which mutates significantly with every emerging
COVID is not yet under control. Despite a bevy of vaccines, monoclonal antibodies, and antivirals, the virus continues to mutate and elude us. One solution that scientists have been exploring since the early days of the pandemic may come in the form of tiny antibodies derived from llamas, which target various parts of the SARS-CoV-2 spike protein.
Hearts from mice infected with COVID-19 have an increased percentage of fibrosis and dilation of the fibers—a common indicator of early cardiomyopathy in mice. Image courtesy of Andrew Marks. Scientists find that COVID-19 infection can cause changes in calcium channels that can affect how the heart beats, it can also trigger inflammation and oxidative stress
A team led by McMaster University researchers Gilmar Reis and Edward Mills has discovered that a single injection of pegylated interferon lambda can successfully treat COVID-19 in people early in the disease. A team led by McMaster University researchers Gilmar Reis and Edward Mills has discovered that a single injection of pegylated interferon lambda (lambda)
By addressing molecules governing how host cells respond to the SARS-CoV-2 virus, researchers hope they’ve found a new therapeutic target less vulnerable to potential drug resistance and emerging variants of concern Researchers at University of California San Diego and UC Riverside have further elucidated the molecular pathway used by the SARS-CoV-2 virus to infect human
